Comerica Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Comerica Bank’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$7.68M	Hold	4,600,000	–	–	0.03%	426
2025 Q3	$7.77M	Hold	4,600,000	–	–	0.03%	499
2025 Q2	$4.17M	Buy	4,600,000 +1,600,000	+53%	+$949K	0.02%	758
2025 Q1	$1.35M	Buy	3,000,000 +2,200,000	+275%	+$1.29M	0.01%	1328
2024 Q4	$402K	Buy	800,000 +550,000	+220%	+$404K	﹤0.01%	1984
2024 Q3	$226K	Hold	250,000	–	–	﹤0.01%	2246
2024 Q2	$249K	Sell	250,000 -295	-0.1%	-$326	﹤0.01%	2167
2024 Q1	$370K	Buy	250,295 +250,000	+84,746%	+$283K	﹤0.01%	2029
2023 Q4	$322	Hold	295	–	–	﹤0.01%	3686
2023 Q3	$348	Buy	+295	New	+$401	﹤0.01%	3738

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Comerica Bank's LCTX Position: Q4 2025 in Review

Comerica Bank held its Lineage Cell Therapeutics (LCTX) position steady in Q4 2025 at 4,600,000 shares worth $7.68M. The position accounts for 0.03% of the portfolio, ranked #426.

Comerica Bank first reported a position in LCTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $7.77M in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

Comerica Bank held 4,600,000 shares of Lineage Cell Therapeutics worth $7.68M as of Q4 2025.
Comerica Bank left its Lineage Cell Therapeutics share count unchanged in Q4 2025.
Lineage Cell Therapeutics made up 0.03% of Comerica Bank's portfolio in Q4 2025, its #426 holding.
Comerica Bank first reported a position in Lineage Cell Therapeutics in Q3 2023 and has held it in 10 quarters since.
Comerica Bank's Lineage Cell Therapeutics position peaked at $7.77M in Q3 2025.
123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.